Selank Dosage (5 mg Vial) Protocol dosage chart
This Selank dosage chart explains how a 5 mg vial can be calculated for intranasal research with a verified 0.10 mL metered actuator. Published human Selank studies primarily used intranasal drops or measured intranasal solution. A measured 5 mL final volume provides 100 mcg per spray, while a measured 10 mL final volume provides 50 mcg per spray.
- Primary human research route
- Intranasal drops or measured intranasal solution.
- 5 mL final volume
- 1 mg/mL, 100 mcg per verified 0.10 mL spray, and 50 nominal sprays.
- 10 mL final volume
- 0.5 mg/mL, 50 mcg per verified 0.10 mL spray, and 100 nominal sprays.
- Device check
- Confirm the pump output and follow its priming instructions before using the calculation.
- Research context
- Human studies used different amounts, durations, and manufactured drop formulations.
Dosing schedule
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL Spray |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 1,000 mcg/mL | 100 mcg50 nominal sprays |
| 10.0 mL | About 7.0 mL | 500 mcg/mL | 50 mcg100 nominal sprays |
Mathematical Actuator Equivalents
| Literature Amount | 5 mL Option100 mcg per Spray | 10 mL Option50 mcg per Spray |
|---|---|---|
| 300 mcg | 3 sprays | 6 sprays |
| 900 mcg | 9 sprays | 18 sprays |
| 2,700 mcg | 27 sprays | 54 sprays |
Mathematical Actuator Equivalents
| Source | Research Context | Published Intranasal Amount and Formulation |
|---|---|---|
| Zozulia et al., 2008 | 62 adults with generalized anxiety disorder or neurasthenia | Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14. |
| Syunyakov et al., 2012 | 20 adults with generalized anxiety disorder | 2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure. |
| Panikratova et al., 2020 | Healthy-volunteer functional connectivity study | One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount. |
Core Formula
| Verified Actuator Output | 5 mL Option1,000 mcg/mL | 10 mL Option500 mcg/mL |
|---|---|---|
| 0.05 mL | 50 mcg | 25 mcg |
| 0.10 mL | 100 mcg | 50 mcg |
| 0.13 mL | 130 mcg | 65 mcg |
Published Human Intranasal Selank Research
Human Selank research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.
The current manufacturer instruction describes a 0.15% nasal-drop product at 1.5 mg/mL, with two drops placed in each nasal passage three times daily for 14 days. Those drop counts belong to the registered bottle and finished formulation. They are not direct equivalents to a different metered pump.
Reference concentration: Mathematically, 5 mg brought to about 3.33 mL equals 1.5 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not a reproduction of the registered preserved drop product.
Nasal Spray Actuator Math
A 0.10 mL actuator is a common nasal pump configuration, but pump output is not universal. Pharmaceutical literature reports pump volumes from approximately 0.025 mL to 0.20 mL per spray. Use the manufacturer specification or a validated measurement for the exact device.
mcg per spray = (5,000 mcg / final volume in mL) x verified mL per spray
nominal sprays = final volume in mL / verified mL per spray
- Confirm the stated volume per full actuation for the specific pump.
- Follow the documented priming and repriming procedure.
- Record residual volume and tail-off near bottle exhaustion when estimating usable sprays.
- Keep pump orientation and actuation stroke consistent during the research procedure.
Important Notes
Small measurement and device details can materially change the amount delivered per spray.
- Use a measured final volume, not the bottle capacity mark alone.
- Verify that the actuator releases 0.10 mL per full stroke before applying the main table.
- Prime and reprime exactly as specified for the pump, then record those actuations.
- Keep the bottle upright and use a complete, consistent stroke for each recorded spray.
- Treat the theoretical 50 or 100 sprays as nominal counts because priming and residual hold-up consume part of the volume.
- A 5 mg vial contains 5,000 mcg total. Calculate the complete peptide requirement before modeling any multi-day published protocol.
- Use a validated laboratory handling and stability plan for any custom multidose preparation.
How Intranasal Selank Research Works
Selank is a synthetic heptapeptide based on the tuftsin sequence. Human studies have examined anxiety-related clinical measures, leu-enkephalin metabolism, EEG response patterns, and functional brain connectivity after Selank exposure. Intranasal drops or solution are the delivery methods reported in the primary human research summarized on this page.
The vial calculation is concentration based. Dividing 5,000 mcg by the measured final volume gives mcg per mL. Multiplying that concentration by the verified pump output gives mcg per spray.
Human Research Findings and Observations
Selank findings should be read together with the population, amount, formulation, and study design.
- The 2008 comparative study reported similar anxiety-related effects for Selank and medazepam, with additional anti-asthenic and psychostimulant observations in the Selank group.
- In the 2012 GAD study, 40% of participants were classified as rapid responders during days 1 to 3, while 60% showed a gradual response pattern through day 14.
- The healthy-volunteer neuroimaging study examined functional connectivity after one intranasal Selank exposure rather than a repeated clinical course.
- The current manufacturer instruction lists unpleasant taste sensations and possible allergic reactions among reported adverse effects.
- Pump output, formulation, nasal condition, and administration technique can affect the delivered amount and deposition pattern.
Research Controls That Affect Nasal Delivery
Consistent technique improves the value of recorded research observations.
- Pump specification: Record the stated or measured mL per actuation.
- Priming status: Document first use, repriming, and any missed sprays.
- Actuation technique: Keep bottle orientation, stroke length, and stroke force consistent.
- Nasal condition: Record congestion, irritation, or other conditions that could affect deposition.
- Formulation details: Record the vehicle, final volume, concentration, container, and storage conditions.
- Actuation count: Track sprays from priming through final use to identify tail-off and residual volume.
Nasal Actuator Technique
Use a standardized device procedure so the recorded amount remains consistent across research observations.
- Inspect the labeled concentration and confirm the actuator output before use.
- Prime or reprime the pump according to the manufacturer instructions.
- Keep the bottle in the specified orientation and use one complete, smooth stroke.
- Record each actuation immediately, including priming sprays.
- Wipe the nozzle with a clean material appropriate for the device and replace the cap.
- Return the bottle to its documented storage condition after the research procedure.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Selank is for research use only and not intended for human consumption. Always consult qualified healthcare professionals before considering any peptide therapy.
Selank Dosage (5 mg Vial) Protocol dosage FAQs
What does the Selank Dosage (5 mg Vial) Protocol dosing schedule look like?
5.0 mL — About 2.0 mL — 1,000 mcg/mL — 100 mcg50 nominal sprays; 10.0 mL — About 7.0 mL — 500 mcg/mL — 50 mcg100 nominal sprays. The full table above lists every step with matching syringe units.
How should reconstituted Selank Dosage (5 mg Vial) Protocol be stored?
Once mixed, Selank Dosage (5 mg Vial) Protocol is kept refrigerated at roughly 2–8 °C, protected from light, and never frozen. Unmixed lyophilised powder is the more stable form and is only reconstituted when it is needed.
How many insulin syringe units equal a Selank Dosage (5 mg Vial) Protocol dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is Selank Dosage (5 mg Vial) Protocol approved for human use?
No. Selank Dosage (5 mg Vial) Protocol is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.